Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans

Mazzini, Letizia; Fagioli, Franca; Boccaletti, Riccardo; Mareschi, Katia; Oliveri, Giuseppe; Olivieri, Carlo; Pastore, Ilaria; Marasso, Roberto; Madon, E

doi:10.1080/14660820310014653

Cited by 221 publications

(139 citation statements)

References 9 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…37 The procedures of ex vivo expansion of autologous MSCs and of transplantation are safe and well tolerated. 37,38 MSCs are not immunorejective, and allogeneic cells can be used. 39,40 Thus, MSC treatment is poised for clinical trials in stroke.…”

Section: Mechanisms Of Msc Neurorestorative Effectmentioning

confidence: 99%

Neurorestorative treatment of stroke: Cell and pharmacological approaches

Chen

Chopp

2006

NeuroRX

153

114

View full text Add to dashboard Cite

Summary:There is a compelling need to develop cell and pharmacological therapeutic approaches to be administered beyond the hyperacute phase of stroke. These therapies capitalize on the capacity of the brain for neuroregeneration and neuroplasticity and are designed to reduce neurological deficits after stroke. This review provides an update of bone marrowderived mesenchymal stem cells (MSCs) and select pharmacological agents in clinical use for other indications that promote the recovery process in the subacute and chronic phases after stroke. Among these agents are 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins), erythropoietin (EPO), and phosphodiesterase type 5 (PDE-5) inhibitors and nitric oxide (NO) donors. Both the MSCs and the pharmacologic agents potentiate brain plasticity and neurobehavioral recovery after stroke.

show abstract

Section: Mechanisms Of Msc Neurorestorative Effectmentioning

confidence: 99%

Neurorestorative treatment of stroke: Cell and pharmacological approaches

Chen

Chopp

2006

NeuroRX

153

114

View full text Add to dashboard Cite

show abstract

“…Hoch, Leach - [9] Rat, 4 wk 3 3D collagen (300-500 mm) properties compared with 2D culture. Unlike multilineage potential, proliferation and CFE assays are fairly consistent across 3D studies (Table 4).…”

Section: D Expansionmentioning

confidence: 99%

“…MSCs exhibit promise in the clinical treatment of osteogenesis imperfecta [5], graft-versus-host disease [6], myocardial infarction [7], Crohn's disease [8], and both neurological [9] and inherited diseases [10]. Cellular therapies treating the breadth of these diseases require an exorbitant number of MSCs that varies among several million cells per kilogram of body weight [5,6,8].…”

Section: Introductionmentioning

confidence: 99%

Concise Review: Optimizing Expansion of Bone Marrow Mesenchymal Stem/Stromal Cells for Clinical Applications

Hoch¹,

Leach²

2015

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Bone marrow-derived mesenchymal stem/stromal cells (MSCs) have demonstrated success in the clinical treatment of hematopoietic pathologies and cardiovascular disease and are the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and nervous systems. However, during the requisite two-dimensional (2D) expansion to achieve a clinically relevant number of cells, MSCs exhibit profound degeneration in progenitor potency. Proliferation, multilineage potential, and colony-forming efficiency are fundamental progenitor properties that are abrogated by extensive monolayer culture. To harness the robust therapeutic potential of MSCs, a consistent, rapid, and minimally detrimental expansion method is necessary. Alternative expansion efforts have exhibited promise in the ability to preserve MSC progenitor potency better than the 2D paradigm by mimicking features of the native bone marrow niche. MSCs have been successfully expanded when stimulated by growth factors, under reduced oxygen tension, and in three-dimensional bioreactors. MSC therapeutic value can be optimized for clinical applications by combining system inputs to tailor culture parameters for recapitulating the niche with probes that nondestructively monitor progenitor potency. The purpose of this review is to explore how modulations in the 2D paradigm affect MSC progenitor properties and to highlight recent efforts in alternative expansion techniques. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:643-652

show abstract

“…El implante intraespinal de neuronas generadas a partir de la línea celular humana NT-2 (teratoma) o la administración intravenosa de células de cordón umbilical humano o de médula ósea retrasa la progresión de un modelo de enfermedad de neurona motora en ratones. Existe un ensayo clínico activo con células procedentes de la médula ósea 56 . En cuanto a la posibilidad de conseguir una neurorreparación con células troncales es más remota, ya que ésta debería sustituir neuronas motoras tanto superiores como inferiores e integrarlas en los circuitos corticales del paciente.…”

Section: Regeneración Neurológicaunclassified

Medicina regenerativa con células madre adultas

Chávarri

Pascual-Figal

Cardoso

et al. 2005

Revista Clínica Española

View full text Add to dashboard Cite

En este trabajo se revisa el estado actual de la medicina regenerativa clínica con células madre de adulto en los campos cardiológico, digestivo, corneal y neurológico. Desde el punto de vista cardiológico existe experiencia clínica con progenitores de médula ósea y células de sangre periférica, así como con mioblastos esqueléticos. En el momento actual las células madre del adulto (hematopoyéticas o mesenquimales de médula ósea) constituyen la mejor opción para la regeneración del tejido cardíaco, mostrando los estudios clínicos resultados favorables, sin problemas éticos ni de seguridad. La mayoría de los estudios con mioblastos esqueléticos también han demostrado que contribuyen significativamente a mejorar la función cardíaca, sobre todo la sistólica, aunque tienen el inconveniente no aclarado totalmente, de inducir arritmias ventriculares malignas. Tanto en uno como en otro caso los estudios clínicos están en la fase inicial y se hace necesario nuevos estudios sobre todo randomizados. En el campo digestivo se presenta la experiencia pionera del Hospital La Paz del uso de células madre procedentes de la grasa abdominal en el tratamiento de la patología fistulosa de pacientes con enfermedad de Crohn. En Oftalmología el trasplante de limbo corneal es una práctica reconocida, usándose células del ojo contralateral cuando el daño es en un solo ojo y células de un donante cuando el daño es bilateral. Por último, en el campo neurológico se han identificado diversas zonas del cerebro de mamíferos adultos donde existen células troncales: el hipocampo, la zona subventricular, el bulbo olfatorio y la zona periependimaria de la médula espinal. Por otra parte, es posible obtener neuronas a partir de células troncales adultas procedentes de otros tejidos, como la médula ósea o el tejido adiposo, lo que supondría una fuente prácticamente inagotable de precursores neurales, bien mediante implante directo tras su selección o bien tras su cultivo in vitro. Aunque hasta la fecha la mayor parte de la experimentación es animal, se están poniendo ya en marcha ensayos clínicos de seguridad en esclerosis lateral amiotrófica.

show abstract

Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans

Abstract: Our results appear to demonstrate that the procedures of ex vivo expansion of autologous mesenchymal stem cells and of transplantation into the spinal cord of humans are safe and well tolerated by ALS patients.

Cited by 221 publications

References 9 publications

Neurorestorative treatment of stroke: Cell and pharmacological approaches

Neurorestorative treatment of stroke: Cell and pharmacological approaches

Concise Review: Optimizing Expansion of Bone Marrow Mesenchymal Stem/Stromal Cells for Clinical Applications

Medicina regenerativa con células madre adultas

Contact Info

Product

Resources

About